63rd ASH Annual Meeting and Exposition
December 11-14, 2021
  • Cellular Therapies for Lymphomas
  • Cellular Therapies-Immune Interactions, Lineage Switching and CNS targets
  • Cellular Therapies for ALL
  • Cellular Therapies for Myeloma
  • Allogeneic CARs and CARs for T Cell Lymphomas
  • Cellular Therapies for Low and High Grade Lymphomas
  • Expanding Targets and Cellular Sources for Immunotherapies

704. Cellular Immunotherapies: Cellular Therapies for Lymphomas

91 ASH denotes this abstract as clinically relevant

Manali Kamdar, MD1, Scott R. Solomon, MD2, Jon E. Arnason, et al.

Liso-cel led to a statistically significant and clinically meaningful improvement in EFS compared to SOC as second-line therapy in patients with primary refractory LBCL versus Or relapse ≤ 12 months after first-line therapy. [Nbsp] This also applies to the   major secondary efficacy endpoints (CR rate and PFS). The safety results in second-line treatment were consistent with the Liso-cel safety profile in third-line therapies   or later LBCL. There were no new security concerns.

 

92

Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi, et al.

In this study, there was no OS difference between Axi-Cel and Tisa-Cel. Axi-cel achieved higher ORR and CRR and significantly longer PFS compared to tisa-cel. However, higher efficacy was associated with higher neurotoxicity with Axi-cel. Young and/or fit patients can benefit most from Axi-cel. Tisa-cel is most beneficial for elderly and/or not fit patients.

 

93

Sattva S. Neelapu, Julio C. Chavez, Alison R. Sehgal, et al.

The long-term follow-up in ZUMA-5 showed a significant and sustained benefit for axi-cel in patients with iNHL. In Follicular Lymphoma there were consistently high response rates with a median DOR of 38.6 months. This affected 57 percent of eligible patients. With mantle cell lymphoma, the results seemed to improve with a longer follow-up period: the median DOR and OS had not yet been reached. Axi-cel continued to show a manageable safety profile and no new safety signals emerged.

 

94 ASH denotes this abstract as clinically relevant

JIA Wei, Min Xiao, Zekai Mao, et al.

The CAR-T-cell cocktail therapy is effective in TP53-disturbed r / r aggressive B-NHL. The inclusion of CAR-T cell infusions in the ASCT can further improve the long-term outcome of these patients.

 

95

Nirav N. Shah, Joanna C. Zurko, Dina Schneider, et al.

Bispecific LV20.19 CAR-T cells expanded with IL7 + 15 resulted in an effective high ORR and there were low rates of grade ≥3 CRS or ICANS for R / R-B-cell NHL. The treatment is safe. The MCL outcomes had an ORR of 100 percent without relapses.

 

96

Jae H Park, Craig S. Sauter,  M. Lia Palomba, et al.

Giving anakinra early seems safe and feasible. The IL-1 receptor reduced the rates of both severe CRS and ICANS with comparable response rates in adult patients with R/R-B-cell lymphoma who received CD19-CAR-T cells. Severe CRS and ICANS rates were 6 percent each with relatively little use of tocilizumab (29%) and corticosteroids (19%). The rate of severe ICANS for axicabtagene was 4 percent.

704. Cellular Immunotherapies: Cellular Therapies-Immune Interactions, Lineage Switching and CNS targets

253

Melody Smith, Anqi Dai, Guido Ghilardi, et al.

Exposure to antibiotics, particularly piperacillin-tazobactam, imipenem-cilastatin, and meropenem, in the four weeks prior to therapy were associated with poorer survival. Consult the abstract for more information.

 

254

Thomas Gastinne, Amandine Le Bourgeois, Marianne Coste-Burel, et al.

The administration of two doses of the BNT162b2 mRNA Covid-19 vaccine to recipients of CAR-T therapy leads to a low seroconversion rate (30%). Consult the abstract for more information.

 

255

Wei Jiang, Gaurav Sutrave, Selmir Avdic, et al.

Treatment achieved high 1-year overall survival with low rates of non-relapse mortality and relapse. For more information see the abstract.

 

256

Adam J. Lamble, Regina M. Myers, Agne Taraseviciute, et al.

For more information see the abstract.

 

257

Ying Liu, Biping Deng, Bo Hu, et al.

Sequential CAR-T-cell therapy can lead to a lasting response. Treatment is safe in pediatric Burkitt lymphoma. The authors conclude that patients with secondary CNS involvement can benefit from sequential CAR-T cell therapy.

 

258

Matthew J. Frigault, Jorg Dietrich, Kathleen M.E. Gallagher, et al.

Tisagenlecleucel in r/r PCNSL was safe and effective in a highly refractory population. The majority showed a response according to the IPCG, including responses even more than 12 months. Tisagenlecleucel expands in the peripheral blood and in the CNS with CSF gene signatures. This indicates higher CAR-T cell infiltrates in responding patients. More data will be presented in the oral session.

704. Cellular Immunotherapies: Cellular Therapies for ALL

469

Noelle V Frey, Saar Gill, Wei-Ting Hwang, et al.

Please consult the abstract

 

470

Colleen Annesley, Corinne Summers, Michael A. Pulsiphe, et al.

Please consult the abstract

 

471

Swati Naik, Spyridoula Vasileiou, Ifigeneia Tzannou, et al.

Please consult the abstract

 

472

704. Cellular Immunotherapies: Cellular Therapies for Myeloma

549 ASH denotes this abstract as clinically relevant

704. Cellular Immunotherapies: Allogeneic CARs and CARs for T Cell Lymphomas

649

Lazaros J. Lekakis, Frederick L. Locke, Michael Tees, et al.

Please consult the abstract

 

651
653

Matthew J. Frigault, Yi-Bin Chen, Kathleen M.E. Gallagher, et al.

Please consult the abstract

 

654

704. Cellular Immunotherapies: Cellular Therapies for Low and High Grade Lymphomas

704. Cellular Immunotherapies: Expanding Targets and Cellular Sources for Immunotherapies

826

Chenggong Li, Qi Chang, Jing Wang, et al.

Please consult the abstract

 

Dienstleistungen

  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos

Impressum

Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Kongressorganisatoren beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weitere Finanzierungsquellen werden bei den jeweiligen Berichten aufgeführt. Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren.

Kontakt

Oncoletter
DR. MED. THOMAS FERBER
CH-8200 SCHAFFHAUSEN

info[@]oncoletter.ch

Copyright 2022. All Rights Reserved.
You are using an outdated browser. The website may not be displayed correctly. Close